Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Career Basics

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced
This article has been retracted

Science 15 January 1999:
Vol. 283. no. 5400, pp. 357 - 362
DOI: 10.1126/science.283.5400.357
Prev | Table of Contents | Next

Research Articles

Fusion-Competent Vaccines: Broad Neutralization of Primary Isolates of HIV

Rachel A. LaCasse, Kathryn E. Follis, Meg Trahey, John D. Scarborough, * Dan R. Littman, Jack H. Nunberg dagger

Current recombinant human immunodeficiency virus (HIV) gp120 protein vaccine candidates are unable to elicit antibodies capable of neutralizing infectivity of primary isolates from patients. Here, "fusion-competent" HIV vaccine immunogens were generated that capture the transient envelope-CD4-coreceptor structures that arise during HIV binding and fusion. In a transgenic mouse immunization model, these formaldehyde-fixed whole-cell vaccines elicited antibodies capable of neutralizing infectivity of 23 of 24 primary HIV isolates from diverse geographic locations and genetic clades A to E. Development of these fusion-dependent immunogens may lead to a broadly effective HIV vaccine.

R. A. LaCasse, K. E. Follis, M. Trahey, J. H. Nunberg, The Montana Biotechnology Center and Division of Biological Sciences, University of Montana, Missoula, MT 59812, USA. J. D. Scarborough and D. R. Littman, Howard Hughes Medical Institute, Skirball Institute of Biomolecular Medicine, New York University Medical Center, 540 First Avenue, New York, NY 10016, USA.
*   Present address: Oregon Health Sciences University, Portland, OR 97201, USA.

dagger    To whom correspondence should be addressed. E-mail: nunberg{at}selway.umt.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity.
C. Devito, B. Zuber, U. Schroder, R. Benthin, K. Okuda, K. Broliden, B. Wahren, and J. Hinkula (2004)
J. Immunol. 173, 7078-7089
   Abstract »    Full Text »    PDF »
Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research.
D. M. Koelle and L. Corey (2003)
Clin. Microbiol. Rev. 16, 96-113
   Abstract »    Full Text »    PDF »
Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response.
S. A. Jeffs, C. Shotton, P. Balfe, and J. A. McKeating (2002)
J. Gen. Virol. 83, 2723-2732
   Abstract »    Full Text »    PDF »
AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Failure To Protect and Possible Enhancement of Challenge Infection by Four Cell-Based Vaccines Prepared with Autologous Lymphoblasts.
S. Giannecchini, P. Isola, O. Sichi, D. Matteucci, M. Pistello, L. Zaccaro, D. Del Mauro, and M. Bendinelli (2002)
J. Virol. 76, 6882-6892
   Abstract »    Full Text »    PDF »
Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates.
H. Golding, M. Zaitseva, E. de Rosny, L. R. King, J. Manischewitz, I. Sidorov, M. K. Gorny, S. Zolla-Pazner, D. S. Dimitrov, and C. D. Weiss (2002)
J. Virol. 76, 6780-6790
   Abstract »    Full Text »    PDF »
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
M. Moulard, S. K. Phogat, Y. Shu, A. F. Labrijn, X. Xiao, J. M. Binley, M.-Y. Zhang, I. A. Sidorov, C. C. Broder, J. Robinson, et al. (2002)
PNAS 99, 6913-6918
   Abstract »    Full Text »    PDF »
Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization.
B. K. Chakrabarti, W.-p. Kong, B.-y. Wu, Z.-Y. Yang, J. Friborg, X. Ling, S. R. King, D. C. Montefiori, and G. J. Nabel (2002)
J. Virol. 76, 5357-5368
   Abstract »    Full Text »    PDF »
Role of N-Linked Glycans in a Human Immunodeficiency Virus Envelope Glycoprotein: Effects on Protein Function and the Neutralizing Antibody Response.
M. I. Quinones-Kochs, L. Buonocore, and J. K. Rose (2002)
J. Virol. 76, 4199-4211
   Abstract »    Full Text »    PDF »
Progress Toward a Human CD4/CCR5 Transgenic Rat Model for De Novo Infection by Human Immunodeficiency Virus Type 1.
O. T. Keppler, F. J. Welte, T. A. Ngo, P. S. Chin, K. S. Patton, C.-L. Tsou, N. W. Abbey, M. E. Sharkey, R. M. Grant, Y. You, et al. (2002)
J. Exp. Med. 195, 719-736
   Abstract »    Full Text »    PDF »
Hydrostatic Pressure Induces the Fusion-active State of Enveloped Viruses.
L. P. Gaspar, A. C. B. Silva, A. M. O. Gomes, M. S. Freitas, A. P. D. Ano Bom, W. D. Schwarcz, J. Mestecky, M. J. Novak, D. Foguel, and J. L. Silva (2002)
J. Biol. Chem. 277, 8433-8439
   Abstract »    Full Text »    PDF »
A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response.
P. F. Zhang, P. Bouma, E. J. Park, J. B. Margolick, J. E. Robinson, S. Zolla-Pazner, M. N. Flora, and G. V. Quinnan Jr (2002)
J. Virol. 76, 644-655
   Abstract »    Full Text »    PDF »
Antigenic Properties of the Human Immunodeficiency Virus Envelope during Cell-Cell Fusion.
C. M. Finnegan, W. Berg, G. K. Lewis, and A. L. DeVico (2001)
J. Virol. 75, 11096-11105
   Abstract »    Full Text »    PDF »
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
D. M. Eckert and P. S. Kim (2001)
PNAS 98, 11187-11192
   Abstract »    Full Text »    PDF »
Evolutionary and immunological implications of contemporary HIV-1 variation.
B. Korber, B. Gaschen, K. Yusim, R. Thakallapally, C. Kesmir, and V. Detours (2001)
Br. Med. Bull. 58, 19-42
   Abstract »    Full Text »    PDF »
Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus Macaques.
D. C. Montefiori, J. T. Safrit, S. L. Lydy, A. P. Barry, M. Bilska, H. T. T. Vo, M. Klein, J. Tartaglia, H. L. Robinson, and B. Rovinski (2001)
J. Virol. 75, 5879-5890
   Abstract »    Full Text »    PDF »
The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region.
S. W. Barnett, S. Lu, I. Srivastava, S. Cherpelis, A. Gettie, J. Blanchard, S. Wang, I. Mboudjeka, L. Leung, Y. Lian, et al. (2001)
J. Virol. 75, 5526-5540
   Abstract »    Full Text »
Construction and In Vitro Properties of a Series of Attenuated Simian Immunodeficiency Viruses with All Accessory Genes Deleted.
Y. Guan, J. B. Whitney, M. Detorio, and M. A. Wainberg (2001)
J. Virol. 75, 4056-4067
   Abstract »    Full Text »
Antibody Binding and Neutralization of Primary and T-Cell Line-Adapted Isolates of Human Immunodeficiency Virus Type 1.
J. York, K. E. Follis, M. Trahey, P. N. Nyambi, S. Zolla-Pazner, and J. H. Nunberg (2001)
J. Virol. 75, 2741-2752
   Abstract »    Full Text »
Antibody-Mediated Neutralization of Primary Human Immunodeficiency Virus Type 1 Isolates: Investigation of the Mechanism of Inhibition.
C. Spenlehauer, A. Kirn, A.-M. Aubertin, and C. Moog (2001)
J. Virol. 75, 2235-2245
   Abstract »    Full Text »
Protein Design of an HIV-1 Entry Inhibitor.
M. J. Root, M. S. Kay, and P. S. Kim (2001)
Science 291, 884-888
   Abstract »    Full Text »    PDF »
Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers.
X. Yang, R. Wyatt, and J. Sodroski (2001)
J. Virol. 75, 1165-1171
   Abstract »    Full Text »
Expression and Characterization of a Single-Chain Polypeptide Analogue of the Human Immunodeficiency Virus Type 1 gp120-CD4 Receptor Complex.
T. R. Fouts, R. Tuskan, K. Godfrey, M. Reitz, D. Hone, G. K. Lewis, and A. L. DeVico (2000)
J. Virol. 74, 11427-11436
   Abstract »    Full Text »
Protection of Macaca nemestrina from Disease following Pathogenic Simian Immunodeficiency Virus (SIV) Challenge: Utilization of SIV Nucleocapsid Mutant DNA Vaccines with and without an SIV Protein Boost.
R. J. Gorelick, R. E. Benveniste, J. D. Lifson, J. L. Yovandich, W. R. Morton, L. Kuller, B. M. Flynn, B. A. Fisher, J. L. Rossio, M. Piatak Jr., et al. (2000)
J. Virol. 74, 11935-11949
   Abstract »    Full Text »
Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis.
K. Ikuta, S. Suzuki, H. Horikoshi, T. Mukai, and R. B. Luftig (2000)
Microbiol. Mol. Biol. Rev. 64, 725-745
   Abstract »    Full Text »    PDF »
Structural characterization of the human respiratory syncytial virus fusion protein core.
X. Zhao, M. Singh, V. N. Malashkevich, and P. S. Kim (2000)
PNAS
   Abstract »    Full Text »
The plasma membrane as a combat zone in the HIV battlefield.
R. W. Doms and D. Trono (2000)
Genes & Dev. 14, 2677-2688
   Full Text »
Evidence That the Transition of HIV-1 gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion.
G. B. Melikyan, R. M. Markosyan, H. Hemmati, M. K. Delmedico, D. M. Lambert, and F. S. Cohen (2000)
J. Cell Biol. 151, 413-424
   Abstract »    Full Text »    PDF »
Increased Neutralization Sensitivity and Reduced Replicative Capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees.
T. Beaumont, S. Broersen, A. van Nuenen, H. G. Huisman, A.-M. de Roda Husman, J. L. Heeney, and H. Schuitemaker (2000)
J. Virol. 74, 7699-7707
   Abstract »    Full Text »
Characterization and Epitope Mapping of Neutralizing Monoclonal Antibodies Produced by Immunization with Oligomeric Simian Immunodeficiency Virus Envelope Protein.
A. L. Edinger, M. Ahuja, T. Sung, K. C. Baxter, B. Haggarty, R. W. Doms, and J. A. Hoxie (2000)
J. Virol. 74, 7922-7935
   Abstract »    Full Text »
Current Evidence and Future Directions for Targeting HIV Entry: Therapeutic and Prophylactic Strategies.
M. P. D'Souza, J. S. Cairns, and S. F. Plaeger (2000)
JAMA 284, 215-222
   Abstract »    Full Text »    PDF »
Enhanced Binding of Antibodies to Neutralization Epitopes following Thermal and Chemical Inactivation of Human Immunodeficiency Virus Type 1.
K. Grovit-Ferbas, J. F. Hsu, J. Ferbas, V. Gudeman, and I. S. Y. Chen (2000)
J. Virol. 74, 5802-5809
   Abstract »    Full Text »
Evidence for Viral Virulence as a Predominant Factor Limiting Human Immunodeficiency Virus Vaccine Efficacy.
P. Mooij, W. M. J. M. Bogers, H. Oostermeijer, W. Koornstra, P. J. F. Ten Haaft, B. E. Verstrepen, G. Van Der Auwera, and J. L. Heeney (2000)
J. Virol. 74, 4017-4027
   Abstract »    Full Text »
International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors.
P. M. Murphy, M. Baggiolini, I. F. Charo, C. A. Hebert, R. Horuk, K. Matsushima, L. H. Miller, J. J. Oppenheim, and C. A. Power (2000)
Pharmacol. Rev. 52, 145-176
   Abstract »    Full Text »    PDF »
Sequential CD4-Coreceptor Interactions in Human Immunodeficiency Virus Type 1 Env Function: Soluble CD4 Activates Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120.
K. Salzwedel, E. D. Smith, B. Dey, and E. A. Berger (2000)
J. Virol. 74, 326-333
   Abstract »    Full Text »
A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure.
J. M. Binley, R. W. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D. J. Anselma, P. J. Maddon, W. C. Olson, et al. (2000)
J. Virol. 74, 627-643
   Abstract »    Full Text »
Determinants of Syncytium Formation in Microglia by Human Immunodeficiency Virus Type 1: Role of the V1/V2 Domains.
J. T. C. Shieh, J. Martín, G. Baltuch, M. H. Malim, and F. González-Scarano (2000)
J. Virol. 74, 693-701
   Abstract »    Full Text »
A Human Milk Factor Susceptible to Cathepsin D Inhibitors Enhances Human Immunodeficiency Virus Type 1 Infectivity and Allows Virus Entry into a Mammary Epithelial Cell Line.
K. El Messaoudi, L. F. Thiry, C. Liesnard, N. Van Tieghem, A. Bollen, and N. Moguilevsky (2000)
J. Virol. 74, 1004-1007
   Abstract »    Full Text »
Multiple Charged and Aromatic Residues in CCR5 Amino-terminal Domain Are Involved in High Affinity Binding of Both Chemokines and HIV-1 Env Protein.
C. Blanpain, B. J. Doranz, J. Vakili, J. Rucker, C. Govaerts, S. S. W. Baik, O. Lorthioir, I. Migeotte, F. Libert, F. Baleux, et al. (1999)
J. Biol. Chem. 274, 34719-34727
   Abstract »    Full Text »    PDF »
Determinants of CD4 Independence for a Human Immunodeficiency Virus Type 1 Variant Map outside Regions Required for Coreceptor Specificity.
C. C. LaBranche, T. L. Hoffman, J. Romano, B. S. Haggarty, T. G. Edwards, T. J. Matthews, R. W. Doms, and J. A. Hoxie (1999)
J. Virol. 73, 10310-10319
   Abstract »    Full Text »
Use of a gp120 Binding Assay To Dissect the Requirements and Kinetics of Human Immunodeficiency Virus Fusion Events.
B. J. Doranz, S. S. W. Baik, and R. W. Doms (1999)
J. Virol. 73, 10346-10358
   Abstract »    Full Text »
Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein.
C. Vita, E. Drakopoulou, J. Vizzavona, S. Rochette, L. Martin, A. Menez, C. Roumestand, Y.-S. Yang, L. Ylisastigui, A. Benjouad, et al. (1999)
PNAS 96, 13091-13096
   Abstract »    Full Text »    PDF »
Role of Immune Responses against the Envelope and the Core Antigens of Simian Immunodeficiency Virus SIVmne in Protection against Homologous Cloned and Uncloned Virus Challenge in Macaques.
P. S. Polacino, V. Stallard, J. E. Klaniecki, S. Pennathur, D. C. Montefiori, A. J. Langlois, B. A. Richardson, W. R. Morton, R. E. Benveniste, and S.-L. Hu (1999)
J. Virol. 73, 8201-8215
   Abstract »    Full Text »    PDF »
Constitutive cell surface association between CD4 and CCR5.
X. Xiao, L. Wu, T. S. Stantchev, Y.-R. Feng, S. Ugolini, H. Chen, Z. Shen, J. L. Riley, C. C. Broder, Q. J. Sattentau, et al. (1999)
PNAS 96, 7496-7501
   Abstract »    Full Text »    PDF »
Heterotypic Protection and Induction of a Broad Heterotypic Neutralization Response by Rotavirus-Like Particles.
S. E. Crawford, M. K. Estes, M. Ciarlet, C. Barone, C. M. O'Neal, J. Cohen, and M. E. Conner (1999)
J. Virol. 73, 4813-4822
   Abstract »    Full Text »
Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.
T. L. Hoffman, C. C. LaBranche, W. Zhang, G. Canziani, J. Robinson, I. Chaiken, J. A. Hoxie, and R. W. Doms (1999)
PNAS 96, 6359-6364
   Abstract »    Full Text »    PDF »
A Small Step Toward an Effective HIV Vaccine.
(1999)
Journal Watch (General) 1999, 2
   Full Text »
Substitutions in a Homologous Region of Extracellular Loop 2 of CXCR4 and CCR5 Alter Coreceptor Activities for HIV-1 Membrane Fusion and Virus Entry.
D. J. Chabot and C. C. Broder (2000)
J. Biol. Chem. 275, 23774-23782
   Abstract »    Full Text »    PDF »
Structural characterization of the human respiratory syncytial virus fusion protein core.
X. Zhao, M. Singh, V. N. Malashkevich, and P. S. Kim (2000)
PNAS 97, 14172-14177
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)